These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Citalopram and fluvoxamine in Tourette's disorder. Bajo S; Battaglia M; Pegna C; Bellodi L J Am Acad Child Adolesc Psychiatry; 1999 Mar; 38(3):230-1. PubMed ID: 10087681 [No Abstract] [Full Text] [Related]
31. Anxious depression and response to treatment. Nelson JC Am J Psychiatry; 2008 Mar; 165(3):297-9. PubMed ID: 18316424 [No Abstract] [Full Text] [Related]
32. Torsade de pointes induced by citalopram and amiodarone. Fayssoil A; Issi J; Guerbaa M; Raynaud JC; Heroguelle V Ann Cardiol Angeiol (Paris); 2011 Jun; 60(3):165-8. PubMed ID: 21295285 [TBL] [Abstract][Full Text] [Related]
33. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Schneeweiss S; Patrick AR; Solomon DH; Mehta J; Dormuth C; Miller M; Lee JC; Wang PS Arch Gen Psychiatry; 2010 May; 67(5):497-506. PubMed ID: 20439831 [TBL] [Abstract][Full Text] [Related]
34. Attention to side effects enhances medical adherence. Vinberg M Acta Psychiatr Scand; 2007 Jan; 115(1):82. PubMed ID: 17201871 [No Abstract] [Full Text] [Related]
35. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. Maina G; Albert U; Salvi V; Bogetto F J Clin Psychiatry; 2004 Oct; 65(10):1365-71. PubMed ID: 15491240 [TBL] [Abstract][Full Text] [Related]
36. Quetiapine-induced weight gain and escitalopram. Holzer L; Paiva G; Halfon O Am J Psychiatry; 2005 Jan; 162(1):192-3. PubMed ID: 15625223 [No Abstract] [Full Text] [Related]
37. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Schneeweiss S; Patrick AR; Solomon DH; Dormuth CR; Miller M; Mehta J; Lee JC; Wang PS Pediatrics; 2010 May; 125(5):876-88. PubMed ID: 20385637 [TBL] [Abstract][Full Text] [Related]
38. Fluvoxamine. A review of its safety profile in world-wide studies. Wagner W; Zaborny BA; Gray TE Int Clin Psychopharmacol; 1994; 9(4):223-7. PubMed ID: 7868844 [TBL] [Abstract][Full Text] [Related]
39. [Withdrawal symptoms in connection with the use of selective serotonin reuptake inhibitors (SSRI)]. Gram LF Ugeskr Laeger; 1998 Dec; 160(50):7291-3. PubMed ID: 9859737 [No Abstract] [Full Text] [Related]
40. Complex movement disorder associated with fluvoxamine. Bronner IM; Vanneste JA Mov Disord; 1998 Sep; 13(5):848-50. PubMed ID: 9756160 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]